NZX-listed medical cannabis firm Rua Bioscience has entered into an agreement to buy medical cannabis player Zalm therapeutics for $10 million in equity.
Zalm is a New Zealand-based company chaired by Rob Fyfe and 8.26% owned by a subsidiary of ASX-listed Cann Group.
Rua is issuing the $10m
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
